Please login to the form below

Not currently logged in
Email:
Password:

Valeant

This page shows the latest Valeant news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Latest news

More from news
Approximately 46 fully matching, plus 110 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    $35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.

  • Deal Watch - May 2017 Deal Watch - May 2017

    It is likely that in the next few months companies such as Teva and Valeant that are having a difficult time at the moment will divest parts of their business.

  • Deal Watch March 2017 Deal Watch March 2017

    There are more below the radar (without accompanying numbers), for example: Valeant has granted Glycyx a sublicence to develop products containing methylnaltrexone bromide for oncology indications, and Fuji Pharma has obtained

  • Deal Watch January 2017 Deal Watch January 2017

    Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group. ... 1, 600. Valeant. L'Oreal. Divestment. CeraVe AcneFree AMBI. 1, 300. Forward

  • Deal Watch August 2016 Deal Watch August 2016

    Finally it was interesting to see that Pharming has recovered from Valeant the North American rights to its product Ruconest. ... Pharming did well to get the rights back especially as it resulted in Valeant having to make a $199m write down of its

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

  • ThermiGen appoints Vladimir Paul-Blanc as president ThermiGen appoints Vladimir Paul-Blanc as president

    He previously served Solta Medical - the aesthetics energy device division of Valeant Pharmaceuticals – as its general manager.

  • BMS appoints three independent directors BMS appoints three independent directors

    Robert Bertolini brings strategic and operational leadership experience from Bausch &Lomb, where he recently served as president and chief financial officer prior to the company's sale to Valeant.

  • Valeant appoints Joseph Papa to end CEO uncertainty Valeant appoints Joseph Papa to end CEO uncertainty

    Valeant appoints Joseph Papa to end CEO uncertainty. He will take over from Michael Pearson at the troubled pharma company in May. ... Searle &Company, Novartis and Pharmacia Corporation. He said: “ I am excited to take on the challenge of leading

  • Valeant adds member to board of directors Valeant adds member to board of directors

    Morfit had originally served on Valeant's board of directors between 2007 and 2014. ... Michael Pearson, chairman and CEO of Valeant, said: “ I am pleased to welcome Mason back to the Valeant board of directors. “

  • Valeant adds Robert Hale to board of directors Valeant adds Robert Hale to board of directors

    Valeant adds Robert Hale to board of directors. And Jeffrey Ubben resigns from the board. ... He said: “ I have had a wonderful experience serving as director of Valeant.

More from appointments
Approximately 6 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics